Author:
Matsumoto Morio,Suzuki Kenshi,Kuroda Junya,Taniwaki Masafumi,Sunami Kazutaka,Kosugi Hiroshi,Ando Kiyoshi,Maruyama Dai,Tobinai Kensei,Kher Uma,Farooqui Mohammed,Liao Jason,Marinello Patricia,Matsuda Kenji,Koh Yasuhiro,Shimamoto Takashi,Iida Shinsuke
Funder
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Jun G, Luptakova K, Koizumi H, Iwasaki K, Hiroi S, Soeda J. Patient characteristics, treatment patterns and outcomes among relapsed/refractory multiple myeloma (RRMM) patients in Japan. Blood. 2016;128:5950.
2. Yamabe K, Inoue S, Hiroshima C. Epidemiology and burden of multiple myeloma in Japan: a systematic review [abstract]. Value Health. 2015;18:A449.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. Version 2.2020. https://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf. Accessed 29 June 2020.
4. Rosenblatt J, Avigan D. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality? Blood. 2017;129:275–9.
5. Ribrag V, Avigan DE, Green DJ, Wise-Draper T, Posada JG, Vij R, et al. Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013. Br J Haematol. 2019;186(3):e41–4.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献